Quantbot Technologies LP Purchases 57,633 Shares of Cellebrite DI Ltd. $CLBT

Key Points

• Quantbot Technologies LP significantly increased its stake in Cellebrite DI Ltd. by 68.2%, acquiring an additional 57,633 shares, bringing its total ownership to 142,083 shares valued at approximately $2.76 million.
• Several institutional investors, including Raymond James Financial and American Century Companies, have also boosted their positions, indicating strong interest in the company with institutional ownership at 45.88%.
• Analysts are generally optimistic about Cellebrite DI, with a consensus rating of "Buy" and an average price target of $22.40, despite recent price adjustments from firms like Needham & Company.

Quantbot Technologies LP boosted its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 68.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 142,083 shares of the company's stock after acquiring an additional 57,633 shares during the period. Quantbot Technologies LP owned 0.06% of Cellebrite DI worth $2,761,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. Bosun Asset Management LLC lifted its position in Cellebrite DI by 1.4% during the 4th quarter. Bosun Asset Management LLC now owns 43,307 shares of the company's stock valued at $954,000 after acquiring an additional 584 shares during the period. OneDigital Investment Advisors LLC raised its holdings in Cellebrite DI by 2.5% in the first quarter. OneDigital Investment Advisors LLC now owns 28,591 shares of the company's stock worth $556,000 after buying an additional 688 shares during the last quarter. TD Waterhouse Canada Inc. raised its holdings in Cellebrite DI by 1.8% in the fourth quarter. TD Waterhouse Canada Inc. now owns 47,497 shares of the company's stock worth $1,046,000 after buying an additional 859 shares during the last quarter. Assetmark Inc. purchased a new position in Cellebrite DI in the first quarter worth about $33,000. Finally, HighTower Advisors LLC raised its holdings in Cellebrite DI by 16.3% in the first quarter. HighTower Advisors LLC now owns 14,485 shares of the company's stock worth $281,000 after buying an additional 2,029 shares during the last quarter. 45.88% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

CLBT has been the subject of several recent analyst reports. JPMorgan Chase & Co. decreased their target price on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a report on Monday, May 12th. Lake Street Capital decreased their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating for the company in a report on Friday, August 15th. Wall Street Zen raised shares of Cellebrite DI from a "hold" rating to a "buy" rating in a report on Saturday, August 16th. Finally, Needham & Company LLC decreased their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating for the company in a report on Thursday, August 14th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $22.40.

Cellebrite DI Trading Up 1.3%

NASDAQ CLBT traded up $0.20 during trading hours on Friday, hitting $16.11. 1,663,790 shares of the company's stock traded hands, compared to its average volume of 2,261,916. The business's fifty day moving average price is $14.95 and its two-hundred day moving average price is $17.47. The firm has a market capitalization of $3.86 billion, a P/E ratio of -21.20, a P/E/G ratio of 3.19 and a beta of 1.27. Cellebrite DI Ltd. has a 52 week low of $13.10 and a 52 week high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.01. The company had revenue of $113.28 million during the quarter, compared to analyst estimates of $112.33 million. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The firm's quarterly revenue was up 18.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.10 earnings per share. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.